A man with unsuspected marine eosinophilic gastritis. (Q53679268)

17 May 2018

title

A man with unsuspected marine eosinophilic gastritis. (English)

1 reference

17 May 2018

author name string

Miguel F Carrascosa

1

1 reference

17 May 2018

Juan Corral Mones

2

1 reference

17 May 2018

José R Salcines-Caviedes

3

1 reference

17 May 2018

Javier Gómez Román

4

1 reference

17 May 2018

publication date

14 November 2014

1 reference

17 May 2018

Lancet Infectious Diseases

published in

1 reference

17 May 2018

volume

15

1 reference

17 May 2018

issue

2

1 reference

17 May 2018

page(s)

248

1 reference

17 May 2018

Trimethoprim-sulfamethoxazole therapy for Pneumocystis carinii pneumonitis in children

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Low-dose co-trimoxazole for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Trimethoprim, sulphamethoxazole, bacterial adhesion and polymorphonuclear leucocyte function.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Successful intermittent prophylaxis with trimethoprim/sulfamethoxazole 2 days per week for Pneumocystis carinii (jiroveci) pneumonia in pediatric oncology patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Trimethoprim-sulfamethoxazole revisited

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Limitations of and indications for the use of co-trimoxazole

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Contemporary unconventional clinical use of co-trimoxazole

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Comparison between itraconazole and cotrimoxazole in the treatment of paracoccidiodomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Efficacy of primary chemoprophylaxis against Pneumocystis carinii pneumonia during the first year of life in infants infected with human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Initiating co-trimoxazole prophylaxis in HIV-infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Pneumocystis cariniiPneumonia: An Uncommon Cause of Death in African Patients with Acquired Immunodeficiency Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Pulmonary complications of human immunodeficiency virus infection in Bujumbura, Burundi

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Pulmonary disease associated with the human immunodeficiency virus in Kigali, Rwanda. A fiberoptic bronchoscopic study of 111 cases of undetermined etiology

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Pneumocystis carinii pneumonia and tuberculosis in Tanzanian patients infected with HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

The mortality and pathology of HIV infection in a west African city.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Pneumocystis carinii pneumonia in South African children infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

The high burden of Pneumocystis carinii pneumonia in African HIV-1-infected children hospitalized for severe pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Co-trimoxazole in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Discontinuation of Secondary Prophylaxis againstPneumocystis cariniiPneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Withdrawal of Pneumocystis jirovecii prophylaxis in HIV-infected children under highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Effect of cotrimoxazole on mortality in HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

The cost-effectiveness of cotrimoxazole in people with advanced HIV infection initiating antiretroviral therapy in sub-Saharan Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

HIV-infected ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/μL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Tissue penetration of trimethoprim and sulphonamides

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Reduction in preterm delivery and neonatal mortality after the introduction of antenatal cotrimoxazole prophylaxis among HIV-infected women with low CD4 cell counts

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Randomised, placebo-controlled trial to evaluate co-trimoxazole to reduce mortality and morbidity in HIV-infected post-natal women in Zambia (TOPAZ).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-saharan Africa.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Safety and efficacy of co-trimoxazole for treatment and prevention of Plasmodium falciparum malaria: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Effectiveness of co-trimoxazole to prevent Plasmodium falciparum malaria in HIV-positive pregnant women in sub-Saharan Africa: an open-label, randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Safety of daily co-trimoxazole in pregnancy in an area of changing malaria epidemiology: a phase 3b randomized controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Cotrimoxazole prophylaxis versus mefloquine intermittent preventive treatment to prevent malaria in HIV-infected pregnant women: two randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

The effect of cotrimoxazole prophylactic treatment on malaria, birth outcomes, and postpartum CD4 count in HIV-infected women

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Antiretroviral drugs in the cupboard are not enough: the impact of health systems' performance on mother-to-child transmission of HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Child mortality according to maternal and infant HIV status in Zimbabwe

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Effect of age, polymicrobial disease, and maternal HIV status on treatment response and cause of severe pneumonia in South African children: a prospective descriptive study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Pneumocystis carinii pneumonia in infants who were exposed to human immunodeficiency virus but were not infected: an exception to the AIDS surveillance case definition

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Protective efficacy of co-trimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Effects of cotrimoxazole prophylactic treatment on adverse health outcomes among HIV-exposed, uninfected infants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Adverse reactions to trimethoprim-sulfamethoxazole among children with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Time for new recommendations on cotrimoxazole prophylaxis for HIV-exposed infants in developing countries?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Cotrimoxazole prophylaxis and risk of severe anemia or severe neutropenia in HAART-exposed, HIV-uninfected infants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Role of intestinal mucosal integrity in HIV transmission to infants through breast-feeding: the BAN study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Effect of presumptive co-trimoxazole prophylaxis on pneumococcal colonization rates, seroepidemiology and antibiotic resistance in Zambian infants: a longitudinal cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Impact of cotrimoxazole on carriage and antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae in HIV-infected children in Zambia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Implementation of free cotrimoxazole prophylaxis improves clinic retention among antiretroviral therapy-ineligible clients in Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Translating evidence into policy in low-income countries: lessons from co-trimoxazole preventive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, Côte d'Ivoire

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Antimicrobial susceptibility of bacterial isolates from community acquired infections in Sub-Saharan Africa and Asian low and middle income countries

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Daily trimethoprim-sulfamethoxazole prophylaxis rapidly induces corresponding resistance among intestinal Escherichia coli of HIV-infected adults in Kenya.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Does cotrimoxazole prophylaxis for the prevention of HIV-associated opportunistic infections select for resistant pathogens in Kenyan adults?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Increased disease burden and antibiotic resistance of bacteria causing severe community-acquired lower respiratory tract infections in human immunodeficiency virus type 1-infected children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Community-acquired bloodstream infections in Africa: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Cotrimoxazole prophylaxis by HIV-infected persons in Uganda reduces morbidity and mortality among HIV-uninfected family members

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

High incidence of antimicrobial resistant organisms including extended spectrum beta-lactamase producing Enterobacteriaceae and methicillin-resistant Staphylococcus aureus in nasopharyngeal and blood isolates of HIV-infected children from Cape Town,

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Progressive increase in antimicrobial resistance among invasive isolates of Haemophilus influenzae obtained from children admitted to a hospital in Kilifi, Kenya, from 1994 to 2002

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Ten years of surveillance for invasive Streptococcus pneumoniae during the era of antiretroviral scale-up and cotrimoxazole prophylaxis in Malawi

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Characterisation of community acquired non-typhoidal Salmonella from bacteraemia and diarrhoeal infections in children admitted to hospital in Nairobi, Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Effects of trimethoprim-sulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Effect of cotrimoxazole prophylaxis taken by human immunodeficiency virus (HIV)-infected persons on the selection of sulfadoxine-pyrimethamine-resistant malaria parasites among HIV-uninfected household members.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Impact of cotrimoxazole on non-susceptibility to antibiotics in Streptococcus pneumoniae carriage isolates among HIV-infected mineworkers in South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Trimethoprim-sulfamethoxazole prophylaxis and antibiotic nonsusceptibility in invasive pneumococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

The Impact of HIV Infection and Trimethoprim‐sulphamethoxazole Prophylaxis on Bacterial Isolates from Children with Community‐acquired Pneumonia in South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Hormone replacement therapy and uterine leiomyomas

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Bacterial infections in Wegener's granulomatosis: mechanisms potentially involved in autoimmune pathogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Cotrimoxazole treatment for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Study of sulphamethoxazole in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Immunosuppressive Powers of the Antibacterial Agent Trimethoprim

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Suppression of Thymidine Uptake of Human Lymphocytes by Co-trimoxazole

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Inhibition of Legionella pneumophila multiplication within human macrophages by antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Effects of sulfamethoxazole and trimethoprim on human neutrophil and lymphocyte functions in vitro: in vivo effects of co-trimoxazole.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

The penetration of co-trimoxazole into alveolar macrophages and its effect on inflammatory and immunoregulatory functions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Cell-mediated autoimmunity in patients with Wegener's granulomatosis (WG)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Antibiotic therapy for treatment in relapse of intestinal Crohn's disease. A prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

[Favorable effect of trimethoprim-sulfonamide (Eusaprim) in a case of hemorrhagic rectocolitis]

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Child undernutrition, tropical enteropathy, toilets, and handwashing

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Stunting is characterized by chronic inflammation in Zimbabwean infants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Improved growth and anemia in HIV-infected African children taking cotrimoxazole prophylaxis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Effectiveness of trimethoprim-sulfamethoxazole and metronidazole in the treatment of small intestinal bacterial overgrowth in children living in a slum

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Microbial translocation is a cause of systemic immune activation in chronic HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

The impact of antibiotics on growth in children in low and middle income countries: systematic review and meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Effect of early chemoprophylaxis with co-trimoxazole on nutritional status evolution in HIV-1-infected adults in Abidjan, Côte d'Ivoire

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Mucosal immunity in resource-limited setting: is the battle ground different?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Enteropathies in the developing world: neglected effects on global health

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Trimethoprim-sulphamethoxazole in the treatment of persistent diarrhoea: a double blind placebo controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Bacteremia among children admitted to a rural hospital in Kenya.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Bacteraemia among severely malnourished children infected and uninfected with the human immunodeficiency virus-1 in Kampala, Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Infections in children admitted with complicated severe acute malnutrition in Niger

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Antibiotics as part of the management of severe acute malnutrition

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Gut microbiomes of Malawian twin pairs discordant for kwashiorkor

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

TMP/SMX is still the preferred empiric antibiotic for methicillin-resistant Staphylococcus aureus skin and soft tissue infection in the HIV population

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Burkholderia cepacia septicemia in a patient with acute myeloid leukemia in postchemotherapy bone marrow aplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Q fever and pregnancy: disease, prevention, and strain specificity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Maternofetal consequences of Coxiella burnetii infection in pregnancy: a case series of two outbreaks

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Tuberculosis and trimethoprim-sulfamethoxazole

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Susceptibility of Mycobacterium tuberculosis to sulfamethoxazole, trimethoprim and their combination over a 12 year period in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Cotrimoxazole prophylaxis and tuberculosis risk among people living with HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Trimethoprim/sulfamethoxazole susceptibility of Mycobacterium tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Prevalence, severity, and treatment of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) skin and soft tissue infections in 10 medical clinics in Texas: a South Texas Ambulatory Research Network (STARNet) study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

Antibiotics to promote growth in children?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970892-8

7 January 2021

10.1016/S1473-3099(14)70892-8

Identifiers

DOI

1 reference

17 May 2018

PubMed ID

25467651

1 reference

17 May 2018